In a patient with newly diagnosed primary hyperparathyroidism whose vitamin D level increased from 26 to 38 ng/mL and whose parathyroid hormone (PTH) rose from 59 to 100 pg/mL, what are the appropriate next steps in management?

Rising PTH After Vitamin D Repletion: Confirm Primary Hyperparathyroidism and Proceed with Full Workup

The rising PTH from 59 to 100 pg/mL despite vitamin D improvement from 26 to 38 ng/mL strongly suggests true primary hyperparathyroidism rather than secondary hyperparathyroidism from vitamin D deficiency—you must now confirm the diagnosis with simultaneous calcium and PTH measurements, assess target-organ damage, and determine surgical candidacy. 1

Diagnostic Confirmation

Your patient's biochemical pattern is critical to interpret correctly. The 2025 French Expert Consensus emphasizes that before accepting a diagnosis of primary hyperparathyroidism, you must maintain normal vitamin D levels long-term (>6 months) and rule out all causes of secondary hyperparathyroidism 1. Your patient's vitamin D has improved to 38 ng/mL, which is adequate (>30 ng/mL), yet PTH has paradoxically risen—this is the hallmark of autonomous parathyroid function.

Immediate Laboratory Assessment Required:

• Simultaneous serum calcium (albumin-corrected) and PTH measurement to confirm inappropriate PTH elevation relative to calcium
• 24-hour urine calcium and fractional excretion of calcium (FeCa) to distinguish from familial hypocalciuric hypercalcemia (FHH)—FeCa >2% supports primary hyperparathyroidism, while ≤2% suggests FHH 1
• Serum phosphate (typically low-normal in primary hyperparathyroidism)
• Renal function (eGFR) to assess kidney involvement

Common pitfall: Many clinicians stop vitamin D supplementation when PTH rises, fearing worsening hypercalcemia. This is incorrect—the rising PTH despite vitamin D repletion actually confirms autonomous parathyroid disease rather than nutritional secondary hyperparathyroidism 2, 3.

Target-Organ Assessment

Once primary hyperparathyroidism is confirmed, systematic evaluation for complications is mandatory regardless of symptoms 1:

Renal Evaluation (Grade A++):

• 24-hour urine calcium (already mentioned above for diagnosis)
• Renal imaging: Non-contrast low-dose CT scan is more sensitive than ultrasound for detecting asymptomatic nephrolithiasis or nephrocalcinosis 1
• Refer to nephrology if eGFR <60 mL/min/1.73m² or active kidney stones

Bone Evaluation (Grade A++):

• DEXA scan measuring lumbar spine, femoral neck, and distal 1/3 radius (the radius is particularly important in primary hyperparathyroidism as cortical bone is preferentially affected)
• Spine imaging (X-ray or vertebral fracture assessment) to detect asymptomatic vertebral compression fractures

Vitamin D Management During Workup

Continue vitamin D supplementation to maintain 25(OH)D ≥30 ng/mL (ideally 30-50 ng/mL) while monitoring calcium closely 2, 4, 3. Multiple studies confirm this is safe:

• Meta-analysis of 388 patients showed vitamin D supplementation in primary hyperparathyroidism does not cause hypercalcemia or hypercalciuria when given appropriately 2
• Vitamin D repletion actually reduces PTH levels (mean decrease 16 pg/mL) and alkaline phosphatase without raising calcium 2
• The 2014 International Workshop recommends targeting 25(OH)D ≥50 nmol/L (20 ng/mL) minimum, with ≥75 nmol/L (30 ng/mL) being reasonable 4

Monitor serum calcium every 2-4 weeks during vitamin D repletion. If calcium rises above 11 mg/dL or becomes symptomatic, hold vitamin D temporarily 5.

Determining Surgical vs. Conservative Management

After completing the workup above, apply surgical criteria. While the specific surgical indications aren't fully detailed in the provided guidelines, the French consensus emphasizes that parathyroidectomy should be considered in all patients as it's the only definitive cure 1.

Typical indications for surgery include:

• Age <50 years
• Serum calcium >1 mg/dL above upper limit of normal
• eGFR <60 mL/min/1.73m²
• Nephrolithiasis or nephrocalcinosis
• T-score ≤-2.5 at any site or previous fragility fracture
• 24-hour urine calcium >400 mg/day

If Surgery is Planned:

• Parathyroid imaging (sestamibi scan and/or ultrasound) for surgical localization 1
• Ensure vitamin D is repleted before surgery to reduce risk of severe hungry bone syndrome postoperatively 6

If Surgery is Deferred:

• Continue vitamin D supplementation maintaining 25(OH)D 30-50 ng/mL 4
• Monitor serum calcium every 6 months
• Repeat DEXA every 1-2 years
• Consider bisphosphonates (alendronate) if osteoporosis is present—this improves bone density without affecting calcium 4
• Consider cinacalcet only if hypercalcemia becomes problematic (it lowers calcium but doesn't improve bone density) 4

Critical point: The rising PTH despite vitamin D correction is actually diagnostic confirmation, not a reason to stop vitamin D. The autonomous parathyroid tissue is now "unmasked" by adequate vitamin D levels 7, 8.